Second primary malignancy risk after lymphoma chemotherapy and HSCT determined
Danish researchers have quantified the risk of second primary malignancy in patients with lymphoma who are treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.